Title :

Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT.

Author(s) :

Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Labopin, Myriam [Auteur]
CHU Saint-Antoine [AP-HP]
Mielke, Stephan [Auteur]
Karolinska University Hospital [Stockholm]
Passweg, Jakob [Auteur]
University Hospital Basel [Basel]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Gedde-Dahl, Tobias [Auteur]
Oslo University Hospital [Oslo]
Cornelissen, Jan J. [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Salmenniemi, Urpu [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Reményi, Péter [Auteur]
Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet [Budapest, Hungary]
Socie, Gerard [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Van Gorkom, Gwendolyn [Auteur]
Maastricht University Medical Centre [MUMC]
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Huang, Xiao-Jun [Auteur]
Peking University [Beijing]
Rubio, Marie-Thérèse [Auteur]
IUT Nancy-Brabois
Byrne, Jenny [Auteur]
Nottingham University Hospitals NHS Trust [NUH]
Craddock, Charles [Auteur]
Queens Elizabeth Hospital [Birmingham]
Griškevičius, Laimonas [Auteur]
Vilnius University [Vilnius]
Ciceri, Fabio [Auteur]
San Raffaele Scientific Institute
Mohty, Mohamad [Auteur]
CHU Saint-Antoine [AP-HP]

Journal title :

Bone Marrow Transplant

Abbreviated title :

Bone Marrow Transplant

Publication date :

2023-04-13

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

We compared transplants (HSCT) from matched related siblings (MSD) with those from matched 10/10 and mismatched 9/10 unrelated (UD) and T-replete haploidentical (Haplo) donors in acute myeloid leukemia (AML) in first ...
Show more >We compared transplants (HSCT) from matched related siblings (MSD) with those from matched 10/10 and mismatched 9/10 unrelated (UD) and T-replete haploidentical (Haplo) donors in acute myeloid leukemia (AML) in first complete remission (CR1) achieved after two inductions, a known poor prognostic factor. One thousand two hundred and ninety-five patients were included: MSD (n = 428), UD 10/10 (n = 554), UD 9/10 (n = 135), and Haplo (n = 178). Acute GVHD II–IV was higher in all groups compared to MSD. Extensive chronic (c) GVHD was significantly higher in UD 9/10 (HR = 2.52; 95% CI 1.55–4.11, p = 0.0002) and UD 10/10 (HR = 1.48; 95% CI 1.03–2.13, p = 0.036) and cGVHD all grades were higher in UD 9/10 vs MSD (HR = 1.77; 95% CI 1.26–2.49, p = 0.0009). Non-relapse mortality was higher in all groups compared to MSD. Relapse incidence, leukemia-free, and overall survival did not differ significantly between donor types. Finally, GVHD-free relapse-free survival was lower in HSCT from UD 9/10 (HR = 1.56, 95% CI 1.20–2.03, p = 0.0009) but not in those from UD 10/10 (HR = 1.13, p = 0.22) and Haplo donors (HR = 1.12, p = 0.43) compared to MSD. In conclusion, in AML patients undergoing HSCT in CR1 achieved after two induction courses 10/10 UD and Haplo but not 9/10 UD donors are comparable alternatives to MSD.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-11T23:01:00Z
2024-02-27T12:55:02Z